Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced that data from the ...

An international research team has conceived a dual-component controller for three-phase inverters that can reportedly ...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Pierre Noé, Stéphane Malhouitre, and Benoît Charbonnier, discuss phase change materials for reconfigurable photonic ...

In Malaysia, the country’s public broadcaster, Radio Television of Malaysia, is using modulation monitors and rebroadcast ...

The sequel to Xfer Records' wildly popular synth plugin has finally been released after more than a decade of anticipation, bringing new synth engines, effects, a clip sequencer, built-in arpeggiator ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to ...

Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

Saelig Company, Inc. has introduced the Siglent SSG6082A-V Vector Signal Generator, which provides an output frequency range from 9 kHz to 8 GHz, with AM, FM, and PM analog modulation as well as pulse ...

Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...